Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis
In brief
DFS predicts overall survival if hazard ratio under 0.91 in kidney cancer
A meta-analysis of 13 randomized trials (9,594 patients) found a strong correlation (r = 0.75) between disease-free survival and overall survival in localized renal cell carcinoma. When a treatment reduces the DFS hazard ratio below 0.91, it is likely to improve overall survival. The result supports using DFS as a primary endpoint, but patient-level validation and long-term follow-up are still needed.
- Journal
- Cancer (Q1)
- Published
- 15 August 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Constanza Martinez, David Chen, Russell Leong, Nicholas Lum, Karren Xiao, Laith Almasri, et al.
- PMID
- 42590929
- DOI
- 10.1002/cncr.70567
Why clinicians should know about it
- Picked for Breast and Endocrine Surgery (top studies of the week, 16 August 2026): DFS surrogate for OS in localized RCC
- Picked for Nephrology (top studies of the week, 16 August 2026): DFS as surrogate for OS in localized RCC
- Picked for Urology (top studies of the week, 16 August 2026): DFS surrogate for localized kidney cancer, trial‑level meta‑analysis
Abstract
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. Databases were searched from inception to June 10, 2025. Trial-level surrogacy between DFS and OS was assessed using weighted least-squares meta-regression of log-transformed hazard ratios (HRs), and the surrogate threshold effect was estimated. RESULTS: In total, 25 randomized controlled trials were analyzed; 13 trials, analyzed as 15 study-level units comprising 9594 patients, reported HRs for both OS and DFS. DFS demonstrated a strong correlation with OS (weighted Pearson correlation coefficient, 0.75; 95% confidence level, 0.55-0.91; corresponding coefficient of determination, 0.57). The surrogate threshold effect analysis identified a DFS HR <0.914 as predictive of OS benefit. Funnel plots showed no clear asymmetry, and Egger tests did not indicate significant publication bias. CONCLUSIONS: DFS demonstrated a strong association with OS and may serve as a valid trial-level surrogate end point patients with in localized RCC. A DFS HR <0.914 was more likely to predict an OS benefit. These findings support the use of DFS as a primary end point in localized RCC trials, whereas continued long-term follow-up and future patient-level validation remain important.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.